To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Change from baseline in pain on active movement assessed by a 100 mm visual analogue scale (100 mm, VAS)
Time frame: Baseline, 8 weeks after first drug administration
Change from baseline in Lequesne index
Time frame: Baseline, 8 weeks after first drug administration
Change from baseline in physical examination (tenderness)
Time frame: Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in status according endoscopy
Time frame: Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in gastrointestinal (GI) symptoms score
Time frame: Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in laboratory values
Time frame: Baseline, 8 weeks after first drug administration
Number of Patients with Adverse Events
Time frame: Up to 8 weeks after first drug administration
Assessment of significant change from baseline in physical examination (swelling)
Time frame: Baseline, 8 weeks after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.